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Release of Enzymatically Active Deubiquitinating Enzymes upon
Reversible Capture by Disulfide Ubiquitin Reagents
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Abstract: Deubiquitinating enzymes (DUBs) catalyze the
cleavage of ubiquitin from target proteins. Ubiquitin is post-
translationally attached to proteins and serves as an important
regulatory signal for key cellular processes. In this study, novel
activity-based probes to study DUBs were synthesized that
comprise a ubiquitin moiety and a novel disulfide warhead at
the C-terminus. These reagents can bind DUBs covalently by
forming a disulfide bridge between the active-site cysteine
residue and the ubiquitin-based probe. As disulfide bridges can
be broken by the addition of a reducing agent, these novel
ubiquitin reagents can be used to capture and subsequently
release catalytically active DUBs, whereas existing capturing
agents bind irreversibly. These novel reagents allow for the
study of these enzymes in their active state under various
conditions.
The modification of target proteins with ubiquitin (Ub),
a process called ubiquitination, is a key post-translational
event that regulates a wide range of cellular processes. Ub is
a highly conserved 76 amino acid protein, which is conjugated
to proteins by the formation of an isopeptide bond between
the C-terminus of Ub and a lysine residue or the N-terminus
of a target protein. Ub can also be coupled to other Ub
moieties to form various polyubiquitin chains. Deubiquitinat-
ing enzymes (DUBs) catalyze the cleavage of these isopeptide
bonds, thereby regulating the ubiquitination of target pro-
teins. The human genome encodes about 80 active DUBs,
which can be classified into five classes of cysteine (Cys)
proteases and one class of metalloprotease DUBs.[1] As the
function of many DUBs is still unknown, studying these
enzymes in their active state, either in isolation or as part of
a protein complex, is of great importance. Existing reagents to
study the activity of DUBs include cleavable Ub-containing
substrates[2] and covalently binding activity-based probes
(ABPs)[3] that react with the active-site Cys residue. The
latter have been used in activity profiling, inhibitor screening,
and DUB identification.[3b] However, these ABPs bind
irreversibly to the active site of the DUB, rendering them
inactive. In this study, we developed a Ub-based ABP with
a novel warhead that captures DUBs from cell extracts and
allows for their release in an active state (Scheme 1).
In our probe design, we intended to use reagents that can
reversibly modify thiols as Ub-based ABPs react with the
active-site Cys residue. Many such reagents, if not all, are
highly reactive, and thus unspecific towards Cys residues in
proteins. Therefore, previous methods to modify specific
cysteines relied on the mutation of non-target cysteines to
prevent their modification. For example, GlcNAc-methyl-
thiosulfonate has been used to modify proteins with GlcNAc
moieties on specific cysteines.[4] In these proteins, undesirable
Cys residues were replaced by serine residues. Other known
reagents used for the modification of Cys residues are
disulfides (R’@S@S@R’’), which are less reactive. The Cys
thiolate attacks the disulfide bond, and subsequently a new
asymmetric disulfide is formed in a process named thiol-
specific exchange. Chatterjee and co-workers have used this
approach to generate a ubiquitinated histone complex.[5] They
modified a Cys residue that was introduced in histone 2B by
first activating the thiol using 2,2’-dithiobis(5-nitropyridine)
to form a disulfide. Subsequently, a Ub moiety carrying a
C-terminal aminoethanethiol group was coupled. We
exploited the thiol-specific exchange for the design of
a reversible warhead for our novel DUB ABP. We postulated
that a Ub moiety would direct our disulfide ABP to the
active-site cysteine in DUBs. The glycine residue at posi-
tion 76 of Ub was replaced with methyl disulfide as a warhead
(Scheme 2). We hypothesized that this disulfide moiety would
Scheme 1. Binding of disulfide probes to DUBs and subsequent
release by mild cleavage with a reducing agent.
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undergo thiol-specific exchange
with the active-site Cys residue in
DUBs, thereby forming a covalent
disulfide bond (Scheme 1). The
addition of a mild reducing agent
would then be able to break this
disulfide bond and release enzy-
matically active DUBs.
Three variants of the Ub-based
disulfide probe with different N-
terminal modifications were syn-
thesized; one with a free N-termi-
nus (1, UbSS), one with an N-
terminal biotin affinity tag linked
via a poly(ethylene glycol) (PEG)
spacer (2, biotin–PEG–UbSS), and
one with the fluorescent dye 5-
carboxyrhodamine 110 (3, Rho–
UbSS ; Scheme 2; see also the Sup-
porting Information, Figure S1 a).
Ub1–75 was synthesized by total
chemical solid-phase synthesis.[3c,7]
The N-terminus of Ub1–75 (4) was
subsequently modified with a Boc
group (5a), modified with a PEG
spacer and a biotin moiety (5 b), or
modified with N,N’-Boc-protected 5-carboxyrhoda-
mine 110[6, 8] (5c). The peptides were then cleaved from the
resin using hexafluoroisopropanol (HFIP). 2-(Methyldisulfa-
nyl)ethan-1-amine was coupled to the C-terminus of Ub1–75 as
the warhead (6a–6c). 2-(Methyldisulfanyl)ethan-1-amine was
synthesized as described previously.[9] TFA-mediated depro-
tection and purification yielded probes 1, 2, and 3 (Scheme 2
and Figure S1 a). The probes were analyzed by SDS-PAGE
and LC-MS (Figure S1).
To test whether our novel Ub-based DUB probes
containing the disulfide warhead are able to bind to DUBs
in vitro, we incubated the DUB UCHL3 with the probes UbSS
or biotin–PEG–UbSS and followed the reactions by LC-MS
and gel electrophoresis (Figures 1 a,b and S2). We observed
an increase in the mass of UCHL3 corresponding to the
binding of one probe moiety, which confirmed that these
probes are indeed able to react covalently. At higher
concentrations of UbSS and biotin–PEG–UbSS, additional
bands were observed on the gel, which may represent binding
of the probes to other Cys residues in UCHL3 although
labeling is minimal as shown by LC-MS analysis. To deter-
mine whether the formed probe–DUB complex could be
reduced, we incubated the reaction mixture with 10 mm
dithiothreitol (DTT). As shown in Figures 1a, b and S2, the
probe–UCHL3 complexes are completely reduced, yielding
unlabeled UCHL3 and reduced probe (UbSH). To examine
whether Ub-based disulfide probes can bind to DUBs from
other classes, we incubated fluorescently labeled UbSS (3,
Rho–UbSS) with UCHL3, OTUB2, or USP7 TRAF/catalytic
domain (USP71–560), and monitored the labeling by fluores-
cence scanning of the non-reducing SDS-PAGE gel (Fig-
Scheme 2. Synthesis of disulfide probes 1 (UbSS), 2 (biotin–PEG–UbSS),
and 3 (Rho–UbSS). Ubiquitin lacking the C-terminal glycine (Ub1–75)
was synthesized on resin (4). The N-terminus was modified under
various conditions (a–e). a) Boc2O, DiPEA, NMP; b) PyBOP, DiPEA,
(8-Fmoc-amino)-3,6-dioxaoctanoic acid, NMP; c) piperidine, NMP:
d) biotin, HBTU, HOBt, DiPEA, NMP; e) PyBOP, DiPEA, N,N’-Boc-
protected 5-carboxyrhodamine 110 (Rho),[6] NMP. After cleavage from
the resin (f), the C-terminus was modified with an S@SMe group (g).
Global deprotection yielded the final probes (h). f) HFIP, DCM;
g) PyBOP, Et3N, 2-(methyldisulfanyl)ethan-1-amine, DCM; h) TFA/
H2O/iPr3SiH/PhOH. See the Supporting Information for details.
DCM =dichloromethane, DiPEA= N,N-diisopropylethylamine,
HBTU= O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexa-
fluorophosphate, HFIP = hexafluoroisopropanol, HOBt= 1-hydroxy-
benzotriazole, NMP =N-methyl-2-pyrrolidone, PyBOP= benzotriazol-1-
yl-oxytripyrrolidinophosphonium hexafluorophosphate, TFA = trifluoro-
acetic acid.
Figure 1. a) Binding of UbSS to UCHL3 monitored by mass spectrometry at a molar ratio of UCHL3/
UbSS =1:4. Treatment with DTT shows complete reduction of the complex. Unlabeled UCHL3 is
shown as a reference. Additional peaks are detailed in Figure S2. b) Binding of UbSS to UCHL3 at
different UCHL3/UbSS molar ratios. Treatment with DTT releases reduced probe (UbSH) from the
UbSS–UCHL3 complex. Analysis was done by SDS-PAGE and Coomassie Brilliant Blue staining.
c) Binding of the fluorescent probe Rho–UbSS to OTUB2, UCHL3, and the TRAF/catalytic domain of
USP7 (USP71–560). Analysis was done by SDS-PAGE and Coomassie Brilliant Blue staining or in-gel
fluorescence scanning. DUBs labeled with Rho–UbSS are indicated with an asterisk (*).
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ure 1c). Rho–UbSS bound to all three DUBs as fluorescent
bands with the expected molecular weights were observed
after labeling. In addition, upwards shifts were observed after
staining the gel with Coomassie Brilliant Blue, corresponding
to the binding of one probe moiety to the DUBs. DTT
treatment of the probe–DUB complex resulted in complete
reduction and release of the reduced probe Rho–UbSH from
the DUB.
To determine whether the activity of a DUB could be
restored after reduction, we first reacted UCHL3 with UbSS
and purified the complex by anion exchange chromatography
(Figure 2a). Unlabeled UCHL3 was purified using the same
procedure (Figure 2b). The UbSS–UCHL3 complex was then
either left as is or treated with DTT, after which the enzymatic
activity was monitored using a fluorogenic activity assay. In
this assay, Ub–Rhodamine110 (Ub–Rho110) is cleaved, which
releases fluorescent Rho110. In the absence of DTT, no
cleavage was observed (Figure 2c). However, upon addition
of DTT, Ub–Rho110 was cleaved with similar kinetics as
observed with unlabeled UCHL3, indicating that the disulfide
bond in the UbSS–UCHL3 complex was reduced, and the
activity could be completely restored. The activity of UCHL3
was also monitored using the fluorescent Ub–propargylamide
(PA) DUB ABP Rho–Ub–PA.[3d] Fluorescent bands corre-
sponding to UCHL3 bound to Rho–Ub–PAwere observed for
both unlabeled UCHL3 and DTT-treated UbSS–UCHL3
complexes, but not for untreated UbSS–UCHL3 complexes
(Figure 2d). Correspondingly, upward shifts in the silver-
stained gel were observed for both UCHL3 and DTT-treated
UbSS–UCHL3 complex. UCHL3 released from the UbSS–
UCHL3 complex after reduction showed similar labeling with
Rho–Ub–PA as UCHL3 alone, suggesting that released
UCHL3 regains full activity.
To validate that disulfide probes can also bind to DUBs in
cell extract, we tested whether UbSS can inhibit the binding of
the fluorescent DUB ABP TMR–Ub–PA.[3d] Cell extracts
from HeLa cells were pre-incubated with 1 mm of UbSS,
followed by incubation with 1 mm of TMR–Ub–PA. As shown
in Figure 3a, UbSS almost completely inhibited the labeling of
DUBs by TMR–Ub–PA. The presence of DTT in the assay
did allow for the labeling of DUBs with the TMR–Ub–PA
probe, which suggests that UbSS–DUB complexes are readily
released or not formed in the presence of reducing agent. To
visualize the binding of UbSS to specific DUBs in cell extract,
we overexpressed GFP fusions of the DUBs OTUB1
(Figures 3 b and S4 a), OTUB2 (Figure S4 b), and USP8
(Figure S4 c). Cell extracts were made and incubated with
UbSS or Ub–PA as a positive control. We visualized labeling
by non-reducing SDS-PAGE followed by anti-GFP immuno-
Figure 2. Analytical LC-MS profile of a) UbSS–UCHL3 complex and
b) untreated UCHL3, purified by anion exchange chromatography.
Additional peaks are detailed in Figure S3. c) The enzymatic activity of
untreated and DTT-treated purified UbSS–UCHL3 complex and purified
unlabeled UCHL3 was monitored using a Ub–Rho110 fluorogenic
DUB activity assay. d) The enzymatic activity of untreated and DTT-
treated purified UbSS–UCHL3 complex and purified unlabeled UCHL3
was monitored using the fluorescent DUB probe Rho–Ub–PA.[3d]
Proteins were resolved by non-reducing SDS-PAGE and visualized by
fluorescence scanning or silver staining. Ub* indicates reduced
disulfide probe UbSH (left panel) or Rho–Ub–PA and UbSH (right
panel).
Figure 3. a) Competition experiment in which HeLa cell extract was
incubated with UbSS, followed by DUB labeling with fluorescent TMR–
Ub–PA[3d] in the presence or absence of DTT. Labeled proteins were
visualized using in-gel fluorescence scanning. b) Binding of UbSS or
Ub–PA to overexpressed GFP–OTUB1. GFP–OTUB1–Ub* indicates
GFP–OTUB1 bound to either UbSS (lane 2) or Ub–PA probe (lane 3).
Preincubation with N-methyl maleimide (NMM) was used as a negative
control (lane 4). GFP–OTUB1 was visualized using anti-GFP immuno-
blotting. Actin immunoblotting was used as a loading control. c) A
HeLa cell extract was incubated with biotin-labeled UbSS, and reacted
DUBs were captured on neutravidin resin. DUBs were released from
the resin using DTT. Eluted DUBs and DUBs in the input cell extract
were labeled with the fluorescently labeled ABP TMR–Ub–PA[3d] and
visualized using in-gel fluorescence scanning.
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blotting. Labeling with one UbSS moiety was observed for all
three GFP-fused DUBs, illustrated by a shift in migration on
gel. Moreover, catalytic cysteine mutants showed minimal
labeling (Figure S4), which corroborated that the active-site
cysteine is the main site for modification.
To determine whether we can capture and release active
DUBs from cell extract on resin, we incubated HeLa cell
extracts with biotin–PEG–UbSS. The mixture was then
allowed to bind to neutravidin resin. After washing of the
resin, bound DUBs were eluted with the reducing agents
DTT, TCEP, b-mercaptoethanol, or Cys (Figures 3c and S5).
TMR–Ub–PA was added to the eluted fractions to visualize
active DUBs by in-gel fluorescence scanning. The majority of
DUBs that could be labeled in cell extract could also be
labeled after elution with reducing agent. Notably, the 56 kDa
DUB USP14 (65 kDa after binding of TMR-Ub-PA)[3a,c,f,10]
was not retrieved or not active after elution. This is likely due
to the absence of proteasome after washing the resin. USP14
is known to be activated upon association with the protea-
some.[3a,11] Almost no active DUBs were eluted when no
reducing agents were used. Thus active DUBs can be caught
using our biotin–PEG–UbSS probe and specifically released
under mild reducing conditions.
In conclusion, we have developed a novel type of Ub-
based activity-based probe containing a methyl disulfide
warhead that binds to DUBs by means of active-site-specific
disulfide exchange. We have shown that we can capture
DUBs from cell extract on resin, and elute them by using
reducing agents. The importance of this probe lies in its ability
to isolate active DUBs from their natural environment as cell-
specific post-translational modifications may be present that
regulate DUB activity. Our reversible probe can thus be used
to isolate active DUBs or DUB–protein complexes from cells
to study the activity of specific DUBs in in vitro deubiquiti-
nation assays. To the best of our knowledge, the DUB probes
presented here are the first probes that can capture a specific
family of enzymes and release active enzymes under mild
conditions.
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